Brand-Ad-30-6
 IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 5538 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (584 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References
   Article Tables

 Article Access Statistics
    Viewed323    
    Printed166    
    Emailed0    
    PDF Downloaded190    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR - STUDY LETTER
Year : 2020  |  Volume : 86  |  Issue : 4  |  Page : 445-448

New Drugs and Clinical Trials Rules-2019: What academicians need to know


1 Independent Scholar, Institute of Postgraduate Medical Education and Research (IPGMER), Kolkata, West Bengal, India
2 Junior Resident (Pharmacology), Institute of Postgraduate Medical Education and Research (IPGMER), Kolkata, West Bengal, India
3 Senior Resident (Pharmacology), Diamond Harbor Govt. Medical College and Hospital, Kolkata, West Bengal, India

Date of Web Publication11-May-2020

Correspondence Address:
Dr. Sandeep Lahiry
83/10, RBC Road, Kolkata - 700 124, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijdvl.IJDVL_790_19

Rights and Permissions



How to cite this article:
Lahiry S, Thakur S, Chakraborty DS. New Drugs and Clinical Trials Rules-2019: What academicians need to know. Indian J Dermatol Venereol Leprol 2020;86:445-8

How to cite this URL:
Lahiry S, Thakur S, Chakraborty DS. New Drugs and Clinical Trials Rules-2019: What academicians need to know. Indian J Dermatol Venereol Leprol [serial online] 2020 [cited 2020 Jul 13];86:445-8. Available from: http://www.ijdvl.com/text.asp?2020/86/4/445/284175




Sir,

The New Drugs and Clinical Trials Rules 2019, released by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare (MOH & FW), Government of India, became effective from March 25, 2019, except Chapter 4 (Ethics Committee for Biomedical and Health Research), which became effective after 180 days (i.e. Sep 21, 2019).[1] The new rules (Rule 97 (Rule 122DAA)) supersede existing Part XA and Schedule Y of Drugs and Cosmetics Rules, 1945. However, all existing licenses, orders and directions will remain valid.

These rules shall apply to clinical trials, bioavailability or bioequivalence (BA/BE) studies of new drugs and regulation of ethical committees approving them. The primary objectives of the new rules are:

  1. Promotion of research and development in India
  2. Faster accessibility to new drugs
  3. Predictability and transparency in approval process
  4. Improvement data credibility and accuracy.


[Table 1] highlights major changes in the new rules. Some of the key changes are given below:
Table 1: Major changes in Drugs and Clinical Trial Rules, 2019

Click here to view


  1. For the first time, orphan drug has been defined as one intended to treat a condition affecting less than five lakh people in India. Clinical trial fee has been waived off for such drugs along with the provision of fast-track approval
  2. To promote indigenous drug development, the timelines of approval process has been defined as 30 days. If no objection/query is raised by the CDSCO, the application will be considered “approved”
  3. Provision of post-trial access has been made for patients if the new drug is deemed effective without any alternative. This will be provided free of cost by the sponsor.
  4. It is now clarified that any type of study involving human subjects, except drug trials (as defined in clause J), will be governed by the National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017 formulated by the Indian Council of Medical Research (ICMR).[2] Compensation for any study-related serious adverse events will be decided by the Institutional Ethics Committee (IEC)
  5. CDSCO registration is now mandatory for all IECs to approve regulatory clinical trials. However, accreditation by National Accreditation Board for Hospitals and Healthcare Providers – Quality Council of India (NABH–QCI) is not mandatory, although recommended. For approving non-regulatory trials, all IECs, should be registered with Department of Health Research (MOH & FW).


These new rules are expected to streamline processes for conducting clinical research in India. Provisions like longer renewal period for IEC registrations and waiver of local clinical studies are a welcome step. However, clarification is required regarding provisions like bridging trials for ethnically diverse subject population and regulatory role of the Drug Controller General of India (DCGI), if any, in areas like biomedical and health research, formation of IEC or compensation clauses.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Central Drugs Standard Control Organization. Drug and Clinical Trial Rules. New Delhi: Central Drugs Standard Control Organization; 2019. Available from: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NDI2MQ==. [Last accessed on 2019 Sep 12].  Back to cited text no. 1
    
2.
ICMR. National Ethical Guidelines for Biomedical and Health Research Involving Human Participants. New Delhi: ICMR; 2017. Available from: https://www.icmr.nic.in/sites/default/files/guidelines/ICMR_Ethical_Guidelines_2017.pdf. [Last accessed on 2019 Sep 12].  Back to cited text no. 2
    



 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow